View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
HBV viral kinetics during PEG-IFN 225<br />
12. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative<br />
real-time detection assay for hepatitis B virus DNA and comparison with two commercial<br />
assays. J Clin Microbiol 2000;38:2897-901.<br />
13. Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS. Modeling viral and drug<br />
kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis<br />
2003;23 Suppl 1:13-8.<br />
14. Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, Markatou M, Perelson AS.<br />
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological<br />
responders from nonresponders. Hepatology 2006;43:943-53.<br />
15. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in<br />
hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:4398-402.<br />
16. Sypsa VA, Mimidis K, Tassopoulos NC, Chrysagis D, Vassiliadis T, Moulakakis A, Raptopoulou<br />
M, Haida C, Hatzakis A. A viral kinetic study using pegylated interferon alfa-2b and/or<br />
lamivudine in patients with chronic hepatitis B/HBeAg negative. Hepatology 2005;42:77-<br />
85.<br />
17. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in<br />
genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon<br />
alfa-2b plus ribavirin. Hepatology 2002;35:930-6.<br />
18. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferonalpha-2b<br />
improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral<br />
Hepat 2003;10:271-6.<br />
19. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis<br />
2003;23 Suppl 1:23-8.<br />
20. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman<br />
ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated<br />
interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology<br />
2001;34:395-403.<br />
21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD,<br />
Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon<br />
alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet<br />
2001;358:958-65.<br />
22. Chow WC, Manns M, Paik SW, Berg T, Piratvisuth T, Chang WY, Lau GKK, Marcellin P, Gane E,<br />
Pluck N. Effect of ethnicity, genotype, gender, age and bodyweight on sustained response<br />
in a large, randomised study of peginterferon (40KD) +/- lamivudine for HBeAG-positive<br />
chronic hepatitis B. Hepatology 2005;42 (Suppl. 1):576A.<br />
23. Wolters LM, Hansen BE, Niesters HG, Levi-Drummer RS, Neumann AU, Schalm SW, de Man<br />
RA. The infl uence of baseline characteristics on viral dynamic parameters in chronic hepatitis<br />
B patients treated with lamivudine. J Hepatol 2002;37:253-8.<br />
24. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from<br />
patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-9.